Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17


1. Catanese VM, Kahn DR: Secondary forms of diabetes. In Principles and Practice of Endocrinology and Metabolism. Edited by Becker KL, Bremner WJ, Hung W, et al. Philadelphia: JB Lippincott; 1995:1220–1228.

2. Argetsinger L, Carter-Su C: Mechanism of signaling by growth hormone receptor. Physiol Rev 1996, 76:1089–1107.

3. Foss MC, Saad MJ, Paccola GM, et al.: Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991, 72:1048–1053.

4. Thorner MO,Vance ML, Laws ER, et al.: The anterior pituitary. In Williams Textbook of Endocrinology, edn 9. Edited by Wilson JD, Foster DW, Kronenberg HM, Larsen PR. Philadelphia:WB Saunders; 1998: 296.

5. Orskov L, Schmitz O, Jorgensen JOL, et al.: Influence of growth hormone on glucose-induced glucose uptake in normal men as assessed by the hyperglycemic clamp technique. J Clin Endocrinol Metab 1989, 68:276–282.

6. Thirone ACP, Carvalho CRO, Brenelli SL, et al.: Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues. Mol Cell Endocrinol 1997, 130:33–42.

7. Sugimoto M,Takeda N, Nakashima K, et al.: Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. Metabolism 1998, 47:783–787.

8. Ezzat S, Ren SG, Braunstein GD, et al.: Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992, 75:1459–1463.

9. Koop BL, Harris AG, Ezzat S: Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994, 130:581–586.

10. Imai E, Stromstedt PE, Quinn PG, et al.: Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1990, 10:4712–4719.

11. Valera A, Pujol A, Pelegrin M, et al.: Transgenic mice overexpressing phos-phoenolpyruvate carboxykinase develop non-insulin-dependent diabetes. Proc Natl Acad Sci U S A 1994, 91:9151–9154.

12. Nyirenda MJ, Lindsay RS, Kenyon CJ, et al.: Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 1998, 101:2174–2181.

13. O’Brien RM, Granner DK: Regulation of gene expression by insulin. Biochem J 1991, 278:609–619.

14. Ishizuka T, Nagashima T, Kajita K, et al.: Effect of glucocorticoid receptor antagonist RU 38486 on acute glucocorticoid-induced insulin resistance in rat adipocytes. Metabolism 1997, 46:997–1002.

15. Weinstein SP, Paquin T, Pritsker A, et al.: Glucocorticoid-induced insulinresistance: dexamethasone inhibits the activation of glucose transport inrat skeletal muscle by both insulin- and non–insulin-related stimuli.Diabetes 1995, 44:441–445.

16. Dimitriadis G, Leighton B, Parry-Billings M, et al.: Effects of glucocorticoidexcess on the sensitivity of glucose transport and metabolism toinsulin in rat skeletal muscle. Biochem J 1997, 321:707–712.

17. Saad MJA, Folli F, Kahn JA, et al.: Modulation of insulin receptor, insulinreceptor substrate-1, and phosphatidylinositol 3-kinase in liver andmuscle of dexamethasone-treated rats. J Clin Invest 1993, 92:2065–2072.

18. Delaunay F, Khan A, Cintra A, et al.: Pancreatic beta cells are importanttargets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997,100:2094–2098.

19. Gremlich S, Roduit R,Thorens B: Dexamethasone induces posttranslationaldegradation of GLUT2 and inhibition of insulin secretion in isolatedpancreatic beta cells. J Biol Chem 1997, 272:3216–3222.

20. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition ofinsulin secretion. J Clin Invest 1997, 99:414–423.

21. Bani D, Biliotti G, Sacchi TB: Morphological changes in the human endocrine pancreas induced by chronic excess of endogenous glucagon. Virchows Archiv B Cell Pathol 1991, 60:199–206.

22. Keiser HR: Pheochromocytoma and other diseases of the sympatheticnervous system. In Principles and Practice of Endocrinology and Metabolism.Edited by Becker KL, Bremner WJ, Hung W, et al. Philadelphia: JBLippincott; 1995:762–770.

23. Lehr S, Herbst M, Kampermann J, et al.:Adrenaline inhibits depolarizationinducedincreases in capacitance in the presence of elevated intracellularcalcium concentration in insulin secreting cells. FEBS Lett 1997, 415:1–5.

24. Renstrom E, Ding WG,Bokvist K, et al.: Neurotransmitter-induced inhibitionof exocytosis in insulin-secreting beta cells by activation of calcineurin.Neuron 1996, 17:513–522.

25. Capaldo B, Napoli R, Di Marino L, et al.: Epinephrine directly antagonizes insulin-mediated activation of glucose uptake and inhibition of free fatty acid release in forearm tissues. Metab Clin Exp 1992, 41:1146–1149.

26. Laakso M, Edelman SV, Brechtel G, et al.: Effects of epinephrine on insulinmediatedglucose uptake in whole body and leg muscle in humans: roleof blood flow. Am J Physiol 1992, 263:E199–204.

27. Raz I, Katz A, Spencer MK: Epinephrine inhibits insulin-mediated glycogenesisbut enhances glycolysis in human skeletal muscle. Am J Physiol 1991,260:E430–435.

28. Malbon CC, Campbell R:Thyroid hormones regulate hepatic glycogensynthase. Endocrinology 1984, 115:681–686.

29. Dimitriadis GD, Leighton B,Vlachonikolis IG, et al.: Effects of hyperthyroidismon the sensitivity of glycolysis and glycogen synthesis toinsulin in the soleus muscle of the rat. Biochem J 1988, 253:87–92.

30. Holness MJ, Sugden MC: Hepatic carbon flux after re-feeding: hyperthyroidismblocks glycogen synthesis and the suppression of glucoseoutput observed in response to carbohydrate re-feeding. Biochem J1987, 247:627–634.

31. Tosi F, Moghetti P, Castello R, et al.: Early changes in plasma glucagonand growth hormone response to oral glucose in experimental hyperthyroidism.Metabolism 1996, 45:1029–1033.

32. Fryer LG, Holness MJ, Sugden MC: Selective modification of insulin action in adipose tissue by hyperthyroidism. J Endocrinol 1997, 154:513–522.

33. Matthei S,Trost B, Hamann A, et al.: Effect of in vivo thyroid hormonestatus on insulin signalling and GLUT1 and GLUT4 glucose transportsystems in rat adipocytes. J Endocrinol 1995, 144:347–357.

34. Gonzalo MA, Grant C, Moreno I, et al.: Glucose tolerance, insulin secretion, insulin sensitivity and glucose effectiveness in normal and overweight hyperthyroid women. Clin Endocrinol 1996, 45:689–697.

35. Bonadonna RC, DeFronzo RA: Glucose metabolism in obesity and typeII diabetes. In Obesity. Edited by Bjorntorp P, Brodoff BN. Philadelphia:JB Lippincott; 1992:474–501.

36. Sorenson RL, Brejle TC, Hegre OD, et al.: Prolactin (in vitro) decreases theglucose stimulation threshold, enhances insulin secretion, and increasesdye coupling among islet B cells. Endocrinology 1987, 121:1447–1453.

37. Brejle TC, Parsons JA, Sorenson RL: Regulation of islet beta-cell proliferationby prolactin in rat islets. Endocrinology 1994, 43:263–273.

38. Weinhaus AJ, Stout LE, Sorenson RL: Glucokinase, hexokinase, glucosetransporter 2, and glucose metabolism in islets during pregnancy andprolactin-treated islets in vitro: mechanisms for long term up-regulationof islets. Endocrinology 1996, 137:1640–1649.

39. Wade GN, Schneider JE: Metabolic fuels and reproduction in female mammals. Neurosci Biobehav Rev 1992, 16:235–272.

40. Matsuda M, Mori T: Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice. Proc Soc Exp Biol Med 1996, 212:243–247.

41. Reis FM, Reis AM, Coimbra CC: Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 1997, 153:423–428.

42. Sun YS, Brunicardi FC, Druck P, et al.: Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg 1986, 151:130–140.

43. Brunicardi FC, Chaiken RL, Ryan AS, et al.: Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996, 81:3566–3572.

44. Hramiak IM, Finegood DT,Adams PC: Factors affecting glucose tolerance in hereditary hemochromatosis 1. Clin Invest Med 1997, 20:110–118.

45. Stremmel W, Niederau C, Berger M, et al.:Abnormalities in estrogen, androgen, and insulin metabolism in hereditary hemochromatosis. Ann N Y Acad Sci 1988, 526:209–223.

46. Merkel PA, Simonson DC,Amiel SA, et al.: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988, 318:809–814.

47. Shen M, Orwoll ES, Conte JE Jr, et al.: Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med 1989, 86:726–728.

48. Siegel EG, Janjic D,Wollheim CB: Phenytoin inhibition of insulin release. Studies on the involvement of Ca2+ fluxes in rat pancreatic islets. Diabetes 1982, 31:265–269.

49. Helderman JH, Elahi D,Andersen DK, et al.: Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983, 32:106–111.

50. Tucker SJ, Gribble FM, Zhao C, et al.:Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature 1997, 387:179–183.

51. Sandstrom PE: Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pancreatic beta cells. Br J Pharmacol 1993, 110:1359–1362.

52. Sandstrom PE: Bumetanide reduces insulin release by a direct effect on the pancreatic beta cells. Eur J Pharmacol 1990, 187:377–383.

 voltar